Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Tirzepatide

GYMINDA

Eli Lilly · Phase 2 · Active, not recruiting · Enrollment 285

NCT06965413

ArmPopulationDoseWeeksEstimandWeight change
Placebo + TirzepatideObesity or overweightn/r48n/rn/r
RO7204239 low dose + TirzepatideObesity or overweightn/r48n/rn/r
RO7204239 medium dose + TirzepatideObesity or overweightn/r48n/rn/r
RO7204239 high dose + TirzepatideObesity or overweightn/r48n/rn/r